Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study

OBJECTIVE: Voxelotor is a first-in-class sickle hemoglobin–polymerization inhibitor that was approved in 2019 by the US Food and Drug Administration for treatment of patients with sickle cell disease (SCD) aged ≥12 years; in 2021, the approval was extended to children with SCD aged 4 to 11 years. Ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Clark, Idowu, Modupe, Drachtman, Richard, Beaubrun, Anne, Agodoa, Irene, Nguyen, Andy, Lipman, Kelly, Moshkovich, Olga, Murphy, Ryan, Bellenger, M. Alex, Smith, Wally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899137/
https://www.ncbi.nlm.nih.gov/pubmed/36748060
http://dx.doi.org/10.1155/2023/7533111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899137/
https://www.ncbi.nlm.nih.gov/pubmed/36748060
http://dx.doi.org/10.1155/2023/7533111

Ejemplares similares